Press "Enter" to skip to content

Interim Data Show Promising Efficacy of Cerdulatinib in Relapsed, Refractory Follicular Lymphoma – Specialty Pharmacy Times

admin 0

Interim Data Show Promising Efficacy of Cerdulatinib in Relapsed, Refractory Follicular Lymphoma  Specialty Pharmacy Times

A phase 2a study is evaluating cerdulatinib, an oral SYK/JAK inhibitor, in pre-treated patients with relapsed/refractory follicular lymphoma.

“lymphoma cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *